LEGEND BIOTECH CORP-ADR (LEGN) Stock Analyst Ratings

USA • Nasdaq • NASDAQ:LEGN • US52490G1022

17.5 USD
-0.22 (-1.24%)
At close: Jan 30, 2026
17.38 USD
-0.12 (-0.69%)
Pre-Market: 2/2/2026, 8:33:06 AM
Buy % Consensus

83

ChartMill assigns a Buy % Consensus number of 83% to LEGN. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 72.06. This target is 311.79% above the current price.
  • LEGN was analyzed by 24 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about LEGN.
  • In the previous month the buy percentage consensus was at a similar level.
  • LEGN was analyzed by 24 analysts, which is quite many. So the average rating should be quite meaningful.
LEGN Historical Analyst RatingsLEGN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -66 -60 -54 -48 -42 -36 -30 -24 -18 -12 -6 0 10 20 30

Price Target & Forecast

Price Low Median Mean High 17.5048.4874.4672.0695.55 - 177.03% 325.49% 311.79% 446.00%
LEGN Current Analyst RatingLEGN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10 15
Up and Down Grades
Date Firm Action Rating
2026-01-22 TD Cowen Downgrade Buy -> Hold
2026-01-22 HC Wainwright & Co. Maintains Buy -> Buy
2026-01-20 RBC Capital Maintains Outperform -> Outperform
2026-01-07 Oppenheimer Initiate Outperform
2025-12-17 Cantor Fitzgerald Maintains Overweight -> Overweight
2025-12-12 Morgan Stanley Maintains Overweight -> Overweight
2025-12-08 UBS Maintains Buy -> Buy
2025-11-13 Cantor Fitzgerald Maintains Overweight -> Overweight
2025-11-13 RBC Capital Maintains Outperform -> Outperform
2025-11-13 Barclays Maintains Overweight -> Overweight
2025-10-17 HC Wainwright & Co. Maintains Buy -> Buy
2025-10-09 JP Morgan Maintains Overweight -> Overweight
2025-08-25 JP Morgan Maintains Overweight -> Overweight
2025-08-12 RBC Capital Maintains Outperform -> Outperform
2025-08-12 Morgan Stanley Maintains Overweight -> Overweight
2025-07-17 HC Wainwright & Co. Reiterate Buy -> Buy
2025-07-10 Morgan Stanley Maintains Overweight -> Overweight
2025-07-08 HC Wainwright & Co. Reiterate Buy -> Buy
2025-07-02 UBS Maintains Buy -> Buy
2025-05-14 Cantor Fitzgerald Reiterate Overweight -> Overweight
2025-05-14 Truist Securities Maintains Buy -> Buy
2025-04-22 RBC Capital Reiterate Outperform -> Outperform
2025-04-16 HC Wainwright & Co. Reiterate Buy -> Buy
2025-04-08 HC Wainwright & Co. Reiterate Buy -> Buy
2025-03-17 Morgan Stanley Maintains Overweight -> Overweight
2025-03-12 Guggenheim Reiterate Neutral -> Neutral
2025-03-12 HC Wainwright & Co. Maintains Buy -> Buy
2025-01-23 HC Wainwright & Co. Reiterate Buy -> Buy
2025-01-22 HC Wainwright & Co. Reiterate Buy -> Buy
2025-01-21 HC Wainwright & Co. Reiterate Buy -> Buy

LEGEND BIOTECH CORP-ADR / LEGN FAQ

What is the price target for LEGN stock?

24 analysts have analysed LEGN and the average price target is 72.06 USD. This implies a price increase of 311.79% is expected in the next year compared to the current price of 17.5.


How do analysts rate LEGEND BIOTECH CORP-ADR (LEGN)?

The consensus rating for LEGEND BIOTECH CORP-ADR (LEGN) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.


How many analysts have analysed LEGEND BIOTECH CORP-ADR (LEGN)?

The number of analysts covering LEGEND BIOTECH CORP-ADR (LEGN) is 24.